Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 407.70
Bid: 406.40
Ask: 406.60
Change: 6.70 (1.67%)
Spread: 0.20 (0.049%)
Open: 408.90
High: 409.60
Low: 404.30
Prev. Close: 401.00
RTO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Q1 Trading Update

22 Apr 2021 07:00

RNS Number : 2249W
Rentokil Initial PLC
22 April 2021
 

22 April 2021

 

RENTOKIL INITIAL PLC (RTO)

FIRST QUARTER TRADING UPDATE

A strong first quarter, reflecting a strengthening performance in our core Pest Control business supported by continued high growth in Hygiene

 

 

 

(£m)

 

Q1 2021

Growth

 

 

AER

AER

CER

Ongoing Revenue1

 

711.3

12.8%

15.4%

Revenue

 

713.6

12.5%

15.1%

 

Overview of performance (at CER)

We have made a good start to the year, growing Group Ongoing Revenue by 15.4%, of which 9.4% was Organic2 and 6.0% was from acquisitions. Hygiene delivered a 48.5% increase in Ongoing Revenue (up 48.1% Organic), supported by a revenue contribution of £75.7m from one-time disinfection services, reducing, as anticipated, by approximately 25% on the high watermark level of £100m in Q4 2020. Pest Control delivered Ongoing Revenue growth of 10.5% and saw a return to Organic growth of 1.2% in Q1. Recovery in our core businesses, particularly Pest Control, has demonstrated growing momentum over the quarter, and we exited March 2021 with Group Organic growth of 2.5% (excluding disinfection) and Organic growth in Pest Control of 6.3%.

Regional overview (at CER)

North America delivered a very strong performance in Q1, with Ongoing Revenue of £332.6m (an increase of 39.4%), with £263.4m of revenue generated from Pest Control (up 20.7%) and a £53.6m contribution from disinfection services. Trading conditions in our UK & Rest of World operations, which have been severely impacted by lockdowns throughout Q1, are expected to improve significantly over the coming weeks, reflecting progress in the UK's vaccination programme and subsequent easing of lockdown restrictions, and we are therefore expecting performance for the region to rebound strongly in Q2. Our performance in Europe was in line with our expectations for Q1, with Germany, Southern Europe and Latin America (managed out of Europe) in positive growth territory throughout the quarter and with France and Benelux returning to growth in March. The recent reintroduction of lockdowns in parts of Europe, such as France, are likely to result in the recovery of our European markets being several weeks behind the recovery now anticipated in the UK and elsewhere. Our Asia and Pacific regions have also performed as anticipated, with the progress we have seen in Australia and New Zealand supporting our conviction that the lifting of lockdown restrictions is likely to be quickly followed by continued improvements in our core businesses.

Category overview (at CER) 

Our Pest Control category performed very well in Q1, reflecting a return to Organic growth as well as the positive impact of recent acquisitions, including Environmental Pest Service in Florida, completed in Q4 2020. Excluding disinfection, our core Hygiene category declined by 6.2% (down 6.6% Organic) with the pandemic continuing to impact on regular service provision in certain countries, particularly the UK and France. Our core Hygiene operations delivered a significantly improved performance in March (a decline of 3.3%) with positive momentum continuing into April, and we expect a strong recovery in Q2 as trading conditions are anticipated to improve across the majority of our operations. Ongoing Revenue in our Protect & Enhance category declined by 12.3% year on year, held back by ongoing weakness in our Ambius and France Workwear businesses.

M&A

​We signed seven acquisitions in Q1 - six in Pest Control and one in Protect & Enhance (Ambius) - in Australia, Canada, France, Germany, Italy, Spain and Sweden, with combined annualised revenues in the year prior to acquisition of c.£13m. We have built a substantial pipeline of high-quality opportunities and remain confident in our targeted spend of c.£400m in 2021.

Outlook

The ongoing COVID-19 pandemic presents obvious and continued uncertainty. While progress has been made in controlling the virus in certain countries, aided by vaccine roll-out programmes, other countries are seeing rising case numbers and the reintroduction of lockdowns. The path to normality is therefore predicted to be uneven, reflecting regional and country variances, emergence of new strains and vaccine hesitancy. Notwithstanding this, we continue to expect 2021 to be a year of transition with our core services building momentum - as demonstrated by our performance in Q1 - and with disinfection volumes and prices reducing materially from the start of Q2 and leading to a significant unwind as the year progresses.

Commenting on today's announcement Andy Ransom, Chief Executive, said:

"I am very pleased with the performance our colleagues delivered in Q1, in particular the growth momentum achieved by our Pest Control business, and we remain confident in delivering further operational and financial progress in 2021."

 

Enquiries:

 

Investors / Analysts:

Katharine Rycroft

Rentokil Initial plc

07811 270734

 

 

 

 

Media:

Malcolm Padley

Rentokil Initial plc

07788 978199

 

 

 

 

1Ongoing Revenue represents the performance of the continuing operations of the Group (including acquisitions) after removing the effect of disposed or closed businesses.

 

2Organic Revenue represents the growth in Ongoing Revenue excluding the effect of businesses acquired during the year. Acquired businesses are included in organic measures in the year following acquisition, and the comparative period is adjusted to include an estimated full year performance for growth calculations.

 

AER - actual exchange rates; CER - constant 2020 exchange rates

 

This announcement contains statements that are, or may be, forward-looking regarding the Group's financial position and results, business strategy, plans and objectives. Such statements involve risk and uncertainty because they relate to future events and circumstances and there are accordingly a number of factors which might cause actual results and performance to differ materially from those expressed or implied by such statements. Forward-looking statements speak only as of the date they are made and no representation or warranty, whether expressed or implied, is given in relation to them, including as to their completeness or accuracy or the basis on which they were prepared. Other than in accordance with the Company's legal or regulatory obligations (including under the Listing Rules and the Disclosure Guidance and Transparency Rules), the Company does not undertake any obligation to update or revise publicly any forward-looking statement, whether as a result of new information, future events or otherwise. Information contained in this announcement relating to the Company or its share price, or the yield on its shares, should not be relied upon as an indicator of future performance. Nothing in this announcement should be construed as a profit forecast.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTKZGZDVMKGMZM
Date   Source Headline
14th Oct 20224:37 pmRNSHolding(s) in Company
14th Oct 20229:30 amRNSAdditional Listing
13th Oct 20225:42 pmRNSHolding(s) in Company
13th Oct 20223:05 pmRNSHolding(s) in Company
12th Oct 20221:53 pmRNSAcquisition of Terminix Completion
10th Oct 20221:57 pmRNSHolding(s) in Company
10th Oct 20221:52 pmRNSHolding(s) in Company
10th Oct 20221:38 pmRNSHolding(s) in Company
7th Oct 20226:10 pmRNSRentokil Initial
6th Oct 20222:23 pmRNSResult of General Meeting
3rd Oct 20222:36 pmRNSBlock listing Interim Review
30th Sep 202211:42 amRNSDirector Declaration
14th Sep 20225:55 pmRNSDirector/PDMR Shareholding
14th Sep 202212:21 pmRNSDirector/PDMR Shareholding
7th Sep 20222:38 pmRNSPublication of Circular-Prospectus & GM Notice
22nd Aug 20227:00 amRNSHolding(s) in Company
5th Aug 20222:02 pmRNSDirector/PDMR Shareholding
28th Jul 20227:00 amRNS2022 Interim Results
27th Jul 20229:54 amRNSDirector Declaration
18th Jul 20223:11 pmRNSHolding(s) in Company
15th Jul 20225:30 pmRNSHolding(s) in Company
15th Jul 202211:57 amRNSHolding(s) in Company
27th Jun 20222:27 pmRNSPost stabilisation notice - Rentokil Initial Plc
22nd Jun 20224:16 pmRNSHolding(s) in Company
21st Jun 20223:37 pmRNSDirector/PDMR Shareholding
20th Jun 20229:12 amRNSPre stabilisation notice - Rentokil Initial Plc
20th May 202210:20 amRNSDirector/PDMR Shareholding
12th May 20227:00 amRNSResult of AGM
21st Apr 20227:00 amRNSQ1 Trading Update
1st Apr 20227:00 amRNSBlock listing Interim Review
31st Mar 20226:15 pmRNSTotal Voting Rights
30th Mar 20229:44 amRNSAnnual Financial Report
29th Mar 20222:20 pmRNSDirector/PDMR Shareholding
25th Mar 20224:31 pmRNSDirector/PDMR Shareholding
15th Mar 20227:00 amRNSUpdate on Terminix acquisition
14th Mar 202211:00 amRNSAdditional Listing
3rd Mar 20227:00 amRNSFinal Results
2nd Mar 202210:29 amRNSDirector/PDMR Shareholding
28th Feb 20224:47 pmRNSHolding(s) in Company
22nd Dec 20215:38 pmRNSDirector/PDMR Shareholding
21st Dec 20214:09 pmRNSDirector/PDMR Shareholding
16th Dec 20217:00 amRNSFurther re Terminix Acqn S&P reaffirms BBB rating
15th Dec 20212:02 pmRNSDirector/PDMR Shareholding
14th Dec 20217:00 amRNSAcquisition of Terminix by Rentokil Initial plc
22nd Oct 202110:42 amRNSDirector Declaration
21st Oct 20217:00 amRNSQ3 Trading Update
1st Oct 202110:00 amRNSBlock listing Interim Review
28th Sep 20217:00 amRNSNotice of Capital Markets Day
17th Aug 20216:09 pmRNSDirector/PDMR Shareholding
12th Aug 20214:48 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.